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Background: There is limited information on a special subtype of Acute myeloid leukemia (AML) characterized by
>20% myeloblasts and >20% abnormal promyelocytes in bone marrow and peripheral blood.
Objective: The objective of the present investigation was to explore the clinical and laboratory features of seven
patients with AML-M2/M3.
Method: We retrospectively assessed cell morphology, cytochemistry, immunophenotype, cytogenetics, and clinical
features of seven patients with this rare subtype of AML.
Results: All seven cases had thrombocytopenia, coagulation abnormalities, >20% myeloblasts and abnormal
promyelocytes. The PML/RARα fusion gene was present in six patients and two patients presented a mixed PML/
RARα and AML1/ETO genotype. Five cases achieved CR and two cases did not achieve remission and one case
transform into AML-M2 after CR1.
Conclusions: The clinical and laboratory features of seven patients with AML-M2/M3 are demonstrated in the
present study, providing information on the FAB sub-classification.
Keywords: Acute myeloid leukemia (AML), AML-M2/M3 subtype, Mixed phenotype, Myeloblasts, Abnormal
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Acute myeloid leukemia (AML) is characterized by clonal
expansion of myeloid blasts in bone marrow (BM), periph-
eral blood (PB), or other tissues. In the World Health
Organization (WHO) scheme (2008), a myeloid neoplasm
with 20% or more myeloblasts in the PB or BM is consid-
ered to be AML. Acute myeloid leukemia with the gene
rearrangement t (8; 21) (q22; q22); (AML1/ETO), which
is also referred to as the RUNX1 gene, and AML with
the rearrangement t (15; 17) (q22; q12) (PML/RARα)
are considered distinct AML subtypes. In the French-
American-British (FAB) classification scheme for AML,
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monocytes [1-9].
Two cases of AML with simultaneous PML/RARa and
AML1/ETO gene rearrangement have been reported [10].
We have encountered seven cases with myeloblast frac-
tions ranging from 36 − 85% and a fraction of abnormal
promyelocytes from 24 − 49.5%, with one patient pre-
senting with simultaneous AML1/ETO and PML/RARα
fusion genes [11-18]. In this paper, we retrospectively
analyze all seven cases diagnosed as AML-M2/M3,
to present a general picture of the clinical symptoms,
laboratory results, prognosis, and treatment responses
of this unusual AML subtype.Materials and methods
Clinical information
The current study was approved by the Department of
Hematology of the First Affiliated Hospital of Guangzhouis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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from Jan. 2008 to Jun. 2012. Study eligibility criteria in-
cluded availability of bone marrow histology and cytogen-
etic information at the time of referral to the Department
of Hematology. Acute myeloid leukemia was diagnosed
according to the World Health Organization criteria
[1,2,8]. During the study period, seven patients, aged 8 to
76, were newly diagnosed with AML-M2/M3 based on
>30% myeloblasts and >20% abnormal promyelocytes as
well as predominant myeloperoxidase (MPO or POX) and
naphthol AS-D chloroacetate esterase (AS-DCE, or spe-
cific esterase, SE) positive status. Bone marrow smears, PB
smears, and detailed morphological, immunochemical,
and cytogenetic analyses of BM biopsy tissue were con-
ducted for each patient. The myeloid lineage was assessed
using antibodies against CD9, CD11b, CD13, CD15,
CD33, CD34, CD38, CD45, CD56, CD64, CD117, HLA-
DR, and cMPO. The lymphocyte T cell lineage was
assessed using antibodies against CD2, CD3, CD5 and
CD7, while the B cell lineage was assessed using anti-
bodies against CD19, CD20, CD22, and CD79a.
Flow cytometry
The flow cytometer of COULTER EPICS XL type with
488 nm excitation light source was used in the present in-
vestigation, and System II software was employed for ana-
lysis. After calibration with Fluorescent Microspheres and
adjustment Fluorescence compensation of the machine,
three-color fluorescent staining of the same type sample was
done to serve as negative control to exclude nonspecific
fluorescence staining. According to the degree of expression
of CD45 and particle size of SSC, the cells were divided into
granulocytes, monocytes, lymphocytes, immature lympho-
cyte populations and immature myeloid cells group, red
blood cells and debris cells. After analysis of each cell group,
naive cells were determined. The expression of antigen was
analyzed by two-dimensional phenotypic spectrum.
Case studies
Case 1: A 10-year-old male presented with fever
Bone marrow smears showed hyperactivity of the myeloid
lineage; myeloblasts and abnormal promyelocytes together
comprised 100% of the BM cells. Abnormal promyelocytes,
but with no Auer rods, accounted for 38% of all cells. Some
myeloblasts exhibited one or two prominent nucleoli.
Results of immunohistochemistry of BM biopsy tissue
were consistent with AML: MPO(+++), CD117(+++),
TdT(-), CD34(-), L26(-), UCHL-1(+),CD3(-), CD79a partial
(+), Fe(-), and reticular fiber(-) (Figure 1).
Case 2: A 57-year-old male presented with vertigo, pale and
fever
Bone marrow smears revealed hyperactivity of the mye-
loid lineage. Results of a BM biopsy were consistent withAML. Most AML cells were MPO (+), CD20 partial (+),
CD79а partial (+), CD3 partial (+), some CD138 (+), CD4
(-), CD5 (-), Ag (+), and Fe (-).
Case 3: A 57-year-old female presented with mucocutaneous
hemorrhage and fever
In BM smears, the myeloid lineage was hyperactive, with
39.5% myeloblasts and 49% abnormal promyelocytes.
Case 4: A 32-year-old male presented with fever and
mucocutaneous hemorrhage
Results of BM biopsy were consistent with AML: MPO
(+), CD117(+), LCA(+), Ki-67 approximately 20%(+), CD3
(-), CD34(-),TdT(-), CK(-), Ag(++), and Fe(-).
Cases 5: A 76-year-old male presented with dizziness
Bone marrow smears revealed 42.5% myeloblasts and
30% abnormal promyelocytes. Cytochemistry indicated
99% MPO (+) cells. Most cells also appeared AS-DCE
(+). The immunophenotype was MPO (+), CD117 (+),
LCA (+), about 20% Ki-67(+), CD3 (-), CD34 (-), TdT
(-), CK (-), Ag (++), and Fe (-). Cytogenetic analysis
indicated the presence of the PML/RARа fusion gene,
S type. Immunophenotyping by FCM revealed that
76.4% of BM karyocytes were abnormal (group C, red).
Most cells were weakly CD45 (+), while 30.9% were
CD13 (+) 11.6% CD15 (+), 95.5% CD33 (+), 96.5%
CD56 (+), 16.9% CD64 (+), 78.4% CD117 (+), and 84.3%
were positive for the cytoplasmic antigen of cMPO.
Cells were negative for antigens of the lymphocytic
lineage (Figure 2).
Case 6: An 8-year-old male presented with rashes
Bone marrow smears revealed 17% myeloblasts and
49.5% abnormal promyelocytes. Peripheral blood smears
consisted of 36% myeloblasts and 28% promyelocytes.
Cells were positive for the PML/RARа fusion gene, S type,
and the AML1/ETO fusion gene. The immunophenotype
by FCM was approximately 44.9% bone marrow blast
cells. Within this population, 29.6% were CD34/HLA-DR
(+), 6.5% CD15 (+), 0.2% CD14/CD11b (+), and 3.5%
HLA-DR/CD13 (+). No antigens of the lymphocytic lineage
were detected.
Case 7: A 30-year-old female presented with bone pain and
fever
Bone marrow smears revealed 49% myeloblasts and 13%
abnormal promyelocytes, while the cells in the PB smear
were 14% myeloblasts and 13% promyelocytes. The BM
cells harbored both the PML/RARа fusion gene, S type,
and the AML1/ETO fusion gene. Immunophenotyping
by FCM revealed two groups of blast cells. The SSC
lower cell group was approximately 44.9% of the total
and this population was 13.5% CD11b(+), 90.8% CD13
Figure 1 Morphological and immunological characteristics of BM cells in AML-M2/M3 patients. A, B: Bone marrow smears demonstrated
hyperplasia of the myeloid lineage. Myeloblasts and abnormal promyelocytes accounted for >30% of BM cells. Abnormal promyelocytes were
round, oval, or elliptical. The cytoplasm contained intense dust-like azurophilic granulation and some abnormal promyelocytes contained Auer
rods. The nuclear size and shape were irregular; the nucleus could either appear kidney-shape, cerebriform, or even bi-lobed, with inconspicuous
to prominent nucleoli. C: MPO: 99% positive; D: AS-DCE: 70% positive; E: NSE: particle positive; F: NSE positive cells were inhibited by NaF. G-L:
Immunophenotype as determined by FCM for Case 7 showing two distinct groups of blast cells (red and green).
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12.4% CD56(+), 40.3% CD64(+), 88.0% CD117(+), 85.9%
HLA-DR (+), and 97.8% cMPO(+), while no antigens of
other lineages were expressed. The SSC lower cell group
was approximately 48.3% of the total and this population
was 46.6% CD11b(+), 94.9% CD13(+), 17.3% CD14(+),
95.3% CD15(+), 83.0% CD33(+), 26.1%(+) CD56, 70.4%CD64(+), 43.8% CD117(+), 35.0% HLA-DR(+), and 98.9%
cMPO(+). Antigens of other lineages were not expressed
(Figure 3).
Patients’ clinical profiles, the proportions of myelo-
blasts and abnormal promyelocytes in BM and PB smears,
immunocytochemical determination of MPO(+) and
AS-DCE(+) fractions, results of immunophenotyping
Figure 2 FCM of AML-M2/M3 patients. M-Q: Immunophenotype of Case 2 as measured by FCM. R-W: Immunophenotype of Case 3. X:
Immunophenotype of Case 5. Bone marrow karyocytes contained a group of abnormal cells (group C, red) accounting for 76.4% of the total.
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for all seven case patients are summarized in Tables 1,
2, 3, and 4. The majority of cells were positive for anti-
gens of the myeloid lineage and negative for antigens
of the lymphocytic lineage.
Chemotherapy
Five of the six cases were treated by standard chemo-
therapy [17,18] (daunorubicin + cytarabine, DA) combined
with all-trans retinoic acid (ATRA) or arsenic trioxide
(ATO). The other case (case 6) was first treated with
ATRA, compound realgar, and natural indigo tablets
(CRINT), and then given reduced dose DA [19]. After theinitial treatment, 5 cases achieved complete remission
(CR), including one case with recurrence after three
months that transformed into AML-M2 (Case 6). The
average time to achieve CR was 37 days. Two cases did
not achieved remission (including one death). After stem
cell transplantation, patients with AML-M2/M3 might
have prolonged event-free survival (Table 5).
Results
When newly diagnosis, 85.7% of case patients (6/7) had
fever, 71.4% (5/7) had sternum pressing pain, hemorrhagic
symptoms, and anemia, 28.6% (2/7) presented with
hepatomegaly or splenomegaly, 100% had leukocytosis
Figure 3 Y: Nested RT-PCR for Case 7: M: marker. 1 − 7: PML/RARа fusion gene. 1: mutation, type S positive control; 2: patient type S PCR
products; 3: type S positive control; 4: healthy control, type S PCR products; 5: type L positive control; 6: patient type L PCR products; 7: healthy
control, type L PCR products. 8-10: AML1/ETO fusion gene; 8: positive control; 9: patient PCR products; 10: healthy control PCR products.
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reduced hemocytes (all lineages), 100% had coagula-
tion abnormalities, and 85.7% had elevated serum
LDH. All patients had >20% myeloblasts and >20%
abnormal promyelocytes, of which 71.4% had >30%
BM myeloblasts and abnormal promyelocytes. All six
patients tested were MPO (+). Six patients were PML/
RARа positive and two of these patients harbored both
the AML1/ETO and PML/RARа fusion genes. Immu-
nophenotyping (Table 3) showed that BM and PB cells
expressed antigens of the myeloid lineage, including
CD9, CD11b, CD13, CD15, CD33, CD34, CD38, CD45,
CD56, CD64, CD117, HLA-DR, and cMPO.
Discussion
The FAB classification scheme (1976) divided AML into
subtypes based on the morphology of BM or PB cells,
while the current World Health Organization (WHO)
classification system incorporates morphology, cytogen-
etics, molecular genetics, and immunological markers
for the diagnosis of AML subtypes [2,5,8]. Acute mye-
loid leukemia is divided into two subtypes with different
treatments and prognoses, AML-M2 and APL (AML-M3),
depending on the magnitude of the increase in myeloblasts
or abnormal promyelocytes [3-5]. Here, we provide evi-
dence for a mixed phenotype (AML-M2/M3) with the
characteristics of both AML-M2 and AML-M3. The clonalTable 1 AML-M2/M3 case profiles
Variable Case 1 Case 2 Case 3
Aex/age Male/10 Male/57 Female/57
Fever 38.5°C 37.8°C 37.8°C
Sternum pressing pain + ± +
Hepatomegaly or splenomegaly + - +
Hemorrhagic symptoms + - +
+, positive, showed the symptoms; -, negative, no such symptom; ±, the symptomsand temporal relationship between APL and the secondary
AML subtype are usually obscure [20-23]. In fact, a
chimeric M3:M2 case of acute promyelocytic leukemia
was recently presented [24].
According to the diagnostic criteria for AML, AML-M2
is characterized by significantly increased myeloblasts,
while AML-M3 is associated with abnormal promye-
locytes. However, six of our cases meet the diagnostic cri-
teria for both AML-M2 (>30% myeloblasts) and AML-M3
(>30% abnormal promyelocytes). We also observed two
patients with both the AML1/ETO and the PML/RARα
fusion gene. Such cases cannot be classified as AML-M2
or AML-M3, so we suggest a new subtype of AML, AML-
M2/M3 [2,5,8,15-17].
The diagnosis of AML-M2/M3 requires all available
information, including morphology, cytochemistry, immu-
nophenotyping, genetics, and clinical features [2,8]. In
particular, BM cell morphology and the presence of the
PML/RARа and/or AML1/ETO fusion gene define this
subtype, while the immunophenotype is not sufficiently
distinct from previously defined subtypes for diagnosis.
In BM and PB smears, all cases showed a simultaneous
increase in myeloblasts and abnormal promyelocytes. Some
promyelocytes contained dust-like or sparsely distributed
granules. Promyelocyte nuclei were kidney-shape or
even bi-lobed with inconspicuous to prominent nucle-
oli. Some promyelocytes also contained Aure rods.Case 4 Case 5 Case 6 Case 7 %(7/7)
Male/32 Male/76 Male/8 Female/30
38°C 36.8°C 38.4°C 38°C 85.7 (6/7)
+ - + + 71.4 (5/7)
- - - - 28.6 (2/7)
+ + - + 71.4 (5/7)
were not prominent.
Table 2 Laboratory features of 7 patients with AML-M2/M3
Variable Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 Case 7
Higher than Lower than
Normal, n (%) Normal, n(%)
WBC (×109/L) 112 0.8 119.1 60.9 1.5 17.8 10.1 5(71.4) 2(28.6)
RBC (×1012/L) 4.1 1.6 3.3 2.6 2.2 3.8 3.56 0(0.0) 2(28.6)
HB (g/L) 122 57 93 82 77 105 119 0(0.0) 6(85.7)
Platelets (×109/L) 75 18 18 26 52 65 39 0(0.0) 7(100)
LDH (U/L) 294 192 706 383 364 937 1037 6(85.7) 1(14.6)
PT (sec) 15.8 15.1 25.2 15.9 13.5 13.3 13.6 4(57.1) 0(0.0)
Fibrinogen (g/L) 1.4 5.1 0.6 2 3.6 3.1 4.23 2(28.6) 2(28.6)
D-dimer (ng/ml) >10000 1249 3607 3310 821 - 881 6(85.7) 0(0.0)
BM Myeloblasts 62% 47.50% 39.50% 85% 42.50% 17% 49% 7(100) 0(0.0)
BM abnormal
promyelocytes
38% 35.50% 49.50% 11.50% 30% 49.50% 29% 7(100) 0(0.0)
PB Myeloblasts 61% 0 47% 67% 1% 36% 14% 5(71.4) 0(0.0)
PB abnormal
promyelocytes
17% 0 50% 24% 0 28% 13% 5(71.4) 0(0.0)








99% positive - 95% positive
AS-DCE of BM
smears
48% positive 23% positive 70% positive 19% positive >90% positive - 50% positive







WBC, white blood cell count in peripheral blood; RBC, red blood cell count; HB, hemoglobin; LDH, lactate dehydrogenase; PT, prothrombin time; APTT, activated partial thromboplastin time; BM, bone marrow; PB,










Table 3 Immunophenotype of 7 patients with AML-M2/M3 by FCM
No. CD45(blast) CD9 CD13 CD33 CD34 cMPO CD117 HLA-DR CD11b CD15 CD38 CD56 D64
Case 1 81.1 47.5 32.7 46.9 ― ― ― ― ― ― 41.0 ― ―
Case 2 69.0 ― 47.0 62.9 78.1 ― 55.1 85.4 ― ― ― ― ―
Case 3 80.3 93.2 87.2 97.3 16.2 96.4 ― ― ― ― ― ― ―
Case 4 83.7 92.5 ― 97.0 ― 98.9 16.4 ― 12.7 ― ― ― 86.7
Case 5 76.4 ― 30.9 95.5 ― 78.4 78.4 ― ― 11.6 ― 96.5 16.9
Case 6 44.9 CD34/HLA-DR 29.6%, CD15 6.5%, CD14/CD11b 0.2%, HLA-DR/CD13 3.5%
Case 7 84.5
36.2 ― 90.8 82.6 62.3 97.8 88.0 85.9 13.5 40.3 ― 12.4 7.9
48.3 ― 94.9 83.0 ― 98.9 43.8 35.0 46.6 95.3 ― 26.1 70.4
―, these antibodies were expressed in less than 10% of cells.
He et al. Cancer Cell International  (2014) 14:111 Page 7 of 9These morphological characteristics are distinct from
the typical abnormal promyelocytic cells observed in
AML-M3 [1-3].
Immunophenotyping showed that the SSCs expressed
CD9, CD11b, CD13, CD15, CD33, CD34, CD38, CD45,
CD56, CD64, CD117, and HLA-DR, antigens characteristic
of both AML-M2 and AML-M3. Three cases expressed
BM cells strongly positive for CD9 and four cases exhibited
cells strongly positive for CD13 and CD33. Two of 6 cases
exhibited cells with CD117 expression. In addition, CD34,
cMPO, CD117, HLA-DR, CD11b, CD15, CD38, CD56,
and CD64 were expressed in some cases. However, it
is difficult to distinguished AML-M2 from AML-M3
according to immunophenotype [25-27].
It is uncertain whether the two cases with both fusion
genes harbor two genetic rearrangements within the
same clone or two independent clones with different re-
arrangements. Unfortunately, as this was a retrospective
study, no further analysis was possible and there was no
information on how the various FACS and molecular
assays were performed. Further studies are needed to
examine the frequency of this double genetic rearrange-
ment in AML-M2/M3.
Many of the clinical characteristics of AML-M2/M3
are common to other subtypes of leukemia, including
anemia, fever, hemorrhage, and infiltration. However, this
group of patients was prone to DIC, cerebral hemorrhage,
and other serious complications, with high mortality rates.
Moreover, patients showed a trend for recurrence and
transformation into AML-M2 [3,4]. Although some
clinical procedures including transplantation of stem
cell has been proposed in the present investigation, theTable 4 Genetics features of 7 patients with AML-M2/M3
Variable
Case 1 Case 2 Case 3 Case 4
PML-RARa +/S - +/S +/S&L
ETO non non non non
BCR-ABL - + - non
S, short type of PML-RARa; L, long type of PML-RARa; non, not examined.suggestion was preliminary, not original and might not
be general for all similar cases. Anyhow, we analyzed
the treatment effects of ATRA, ATO, or CRINT com-
bined with the DA regimen on seven patients with
AML-M2/M3, whose clinical and laboratory features
were analyzed scientifically and the data revealed that
there were elevated myeloblasts and abnormal promye-
locytes. Because up to now, there has been no uncon-
tested criterion for the FAB sub-classification of AML,
analyzing particular cases of AML without scientific
genaralization of considered particular cases still is of
some significance. Thus, it remains to be investigated in
FAB sub-classification of AML and its clinical treat-
ment. In addition, further studies are needed to examine
the frequency of this double genetic rearrangement in
AML-M2/M3.
At present, there are no guidelines for the treatment of
this new subtype of AML. All of the patients were treated
with ATRA, ATO, or CRINT combined with the DA regi-
men and five achieved complete temporary remission.
Our initial observations suggest that hematopoietic stem
cell transplantation may be beneficial for long-term sur-
vival. Therefore, the significance of the present study was
that the patients with AML could be treated with ATRA,
ATO, or CRINT combined with the DA regimen, and
hematopoietic stem cell transplantation might be benefi-
cial for long-term survival, possibly providing data for the
guidelines for the FAB sub-classification and treatment of
this new subtype of AML.
In the present study, we identified a novel entity of
AML according to FAB classification and examined its
clinical characteristics. Although the “gray-zone” entityTotal
Case 5 Case 6 Case7 + -
+/S +/S +/S 5 1
non + + 2 0
non - non 1 3
Table 5 Follow-up of 7 patients with AML-M2/M3 until 30th june, 2012
Chemotherapy treatment Subsequent Time*
(days, d) Final diagnosisIn our deparmett Treatment
Case 1 3 cycles allo-SCT** 1630d CR
Case 2 4 cycles auto-SCT 1492d CR
Case 3 1 cycle - 3d Death
Case 4 5 cycles allo-SCT 766d CR
Case 5 1 cycle - >29d Non-remission, lost at follow-up
Case 6 4 cycles - 467d Recurrence, transformed into AMLM2
Case 7 1 cycle - 53d CR
allo-SCT, allogeneic stem cell transplantation; auto-SCT: autologous stem cell transplantation.
*closing date: 30 June, 2012.
**the patient had the allo-SCT in another hospital.
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nized since the first proposal of FAB classification in
1976, unfortunately, this issue was not endowed with
clear solution. Later, in a “proposed revised criteria for
the classification of AML” by the FAB cooperative group
in 1985 [28], the potential fermentation concerning dis-
crimination between M2 and M3 has been asserted. The
group noted that M2 was diagnosed when mature mye-
loid cells were over 10%, even though “few” promyelo-
cytes or later cells were present, indicating that M2 does
not contain cases with “massive” promyelocytes. There-
fore, according to the revised FAB criteria, the presented
cases were not totally consistent with M2. In contrast,
blasts percentage >30% did not exclude M3 diagnosis.
Indeed, myeloblasts occupy >30% in about 10% of M3
cases [29]. Microscopic features of promyelocytes in the
presented cases including sparse granules and bilobed
nucleus were characteristics of AML M3 variant. Thus,
we regarded the cases as AML-M2/M3, which remains
to be further explored. Anyhow, the present investiga-
tion added new information for the analysis of AML-
M2/M3.
In conclusion, the clinical and laboratory features of
seven patients with AML-M2/M3 are demonstrated in
the present study, providing information on the FAB
sub-classification.
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